Aura Biosciences financials
$6.150.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$112.8M | -$96.1M | -$85.0M | -$60.3M | -$35.3M |
| Net income | -$106.2M | -$86.9M | -$76.4M | -$58.8M | -$46.2M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-8.95 |
| EBITDA | -$111.7M | -$94.9M | -$83.7M | -$59.1M | -$34.4M |
| Operating cash flow | -$84.7M | -$79.8M | -$63.8M | -$54.6M | -$32.4M |
| Free cash flow | -$85.2M | -$81.1M | -$64.6M | -$55.7M | -$34.5M |
| Diluted shares | 60.3M | 49.7M | 39.6M | 29.9M | 5.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $59.5M | $31.7M | $41.1M | $121.6M | $149.1M |
| Short-term investments | $84.7M | $119.4M | $185.1M | $67.2M | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $169.4M | $182.5M | $255.1M | $223.9M | $160.0M |
| Total liabilities | $32.5M | $30.5M | $29.2M | $28.4M | $7.7M |
| Shareholders' equity | $136.9M | $152.0M | $225.8M | $195.6M | $152.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology